HSBC: The competition moat of large-scale ICL continues to expand, reiterating a "buy" rating for Edicon Holdings (09860.HK) with a target price of HK$10.

According to the Securities Times APP, Morgan Stanley, a major Wall Street investment bank, recently released a research report stating that the competitive moat of large independent clinical laboratories (ICL) continues to expand, mainly due to their early application of artificial intelligence and strengthening of high-end testing capabilities. The Morgan Stanley analysis team predicts that some of the challenges facing the ICL industry will gradually be overcome in the future. Given that Edicon Holdings (09860.HK) has higher performance growth data compared to its peers and a healthier balance sheet, the Morgan Stanley analysis team reiterated their "buy" rating on Edicon Holdings (09860.HK) stock and set a target price of 10 Hong Kong dollars.